Organigram Global Inc.

NASDAQ:OGI

Drug Manufacturers - Specialty & Generic

Healthcare
$0.68 -1.74%

-$0.02 today

Market cap
$95.40M
Beta
1.84
P/E (TTM)
-7.2
EPS (TTM)
-$0.19
52W Low $0.97High $2.24

Volume 0.62M

Average 0.67M

OGI Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Organigram Global Inc.NASDAQ: OGI

Gross Margin · Q2 FY2026 · quarter ended Mar 2026

Gross margin narrows to 27.4%

Gross margin was 27.4% in Q2 FY2026, down 0.6 pp from a year earlier. On a trailing-twelve-month basis it was 35.6%, up 2.9 pp year over year.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
27.4%-9.3 pp QoQ
Last fiscal yearSep 2025
3.7%-26.1 pp YoY
LTMMar 2026
35.6%+2.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.6 pp——
1 year-26.1 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
3.7%
Year-over-year change
-26.1pp

Gross Margin vs competitors

How OGI compares with its peers on the latest reported figures

  • OGI's LTM Mar 2026 gross margin of 35.6% is the 7th highest of the 10 companies compared; the peer median is 56.7%.
  • Its year-over-year change of +2.9 pp is the 4th highest of 9, against a peer median of +1.4 pp.
OGI Competitors Peer median
Gross Margin for OGI and competitors
Company Period LTM level YoY 3-year change
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202699.3% +6.7 pp+8.5 pp
HSDTSolana CompanyLTM Mar 202694.2% +127.8 pp+50.5 pp
ELMDElectromed, Inc.LTM Mar 202678.4% +0.9 pp+2.6 pp
DERMJourney Medical CorporationLTM Mar 202660.4% -4.2 pp+1.1 pp
INFUInfuSystem Holdings, Inc.LTM Mar 202656.7% +3.6 pp+0.9 pp
ACBAurora Cannabis Inc.LTM Mar 202656.6% +2.0 pp-1.4 pp
OGIOrganigram Global Inc.LTM Mar 202635.6% +2.9 pp—
IVAInventiva S.A.FY202533.7% -66.3 pp-106.4 pp
LFCRLifecore Biomedical, Inc.LTM Mar 202631.2% —-3.8 pp
RNACCartesian Therapeutics, Inc.LTM Mar 2026-621.0% -721.0 pp+1.8 pp
Peer median (excluding OGI) 56.7%+1.4 pp+1.1 pp

Competitors are the stored peer set for OGI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue79.16M145.81M149.21M159.84M186.09M
Cost of Revenue107.56M114.24M114.13M112.32M179.26M
Gross Profit(28.4M)31.57M35.07M47.52M6.83M
Gross Margin-35.9%21.7%23.5%29.7%3.7%
Research & Development3.45M5.96M12.19M11.2M10.95M
Selling, General & Admin46.47M59.21M71.68M68.14M86.88M
Operating Expenses63.42M74.72M271.48M83.2M70.24M
Depreciation & Amortization31.03M24.91M23.43M12.08M12.91M
EBITDA(96.71M)10.97M(25.37M)(23.59M)(14.76M)
EBITDA Margin-122.2%7.5%-17.0%-14.8%-7.9%
Operating Income(91.82M)(43.15M)(242.74M)(35.67M)(63.41M)
Operating Margin-116.0%-29.6%-162.7%-22.3%-34.1%
Interest Income003.69M0825.7K
Interest Expense2.96M429K277.85K00
Other Income / Expenses(38.88M)28.78M(184.21M)(9.77M)35.74M
Income Before Tax(130.7M)(14.37M)(233M)(45.44M)(27.66M)
Pre-Tax Margin-165.1%-9.9%-156.2%-28.4%-14.9%
Income Tax Expense0(88K)(3.52M)0(9.89M)
Net Income(130.7M)(14.28M)(229.48M)(45.44M)(17.78M)
Net Margin-165.1%-9.8%-153.8%-28.4%-9.6%
EPS (Basic)(2.04)(0.18)(2.82)(0.48)(0.14)
EPS (Diluted)(2.04)(0.18)(2.82)(0.48)(0.14)
Weighted Avg Shares64.03M80.01M81.29M95.29M127.67M
Weighted Avg Shares (Diluted)64.03M85.3M81.29M95.29M127.67M

Organigram Global Inc.

NASDAQ:OGI

Intrinsic Alpha fair value

Locked

Current Price

$0.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.